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Introduction {#sec004}
============

In South Africa, more than 6500 patients were diagnosed with a laboratory-confirmed first episode of cryptococcal meningitis during 2017, with an estimated incidence risk of 0.1% among HIV-seropositive persons \[[@pntd.0008137.ref001]\]. A third of patients admitted to South African hospitals with cryptococcal meningitis die in hospital \[[@pntd.0008137.ref002]\]. Cryptococcal meningitis is fatal in more than half of treated cases in routine care \[[@pntd.0008137.ref003]\]. Fluconazole monotherapy is not appropriate as a first-line induction-phase treatment but is recommended as an alternative to flucytosine, in combination with amphotericin B. Fluconazole is also recommended for consolidation and maintenance treatment \[[@pntd.0008137.ref004]\]. In an earlier population-based surveillance study of *Cryptococcus neoformans* in Gauteng province, South Africa, fluconazole susceptibility remained largely unchanged between 2002--2003 and 2007--2008. Only 0.6% of incident isolates from 2002--2003 had a fluconazole MIC of ≥16 μg/ml and these isolates also had very low MICs to amphotericin B, voriconazole and posaconazole \[[@pntd.0008137.ref005]\]. In contrast, in a recent Ugandan study, Smith and colleagues documented a substantial increase in fluconazole MICs in 2010--2014 compared to a previous study in 1998--1999. The MIC~50~ and MIC~90~ values were 8 μg/ml and 32 μg/ml respectively in 2010--2014 compared to an MIC~50~ of 4 μg/ml and an MIC~90~ of 8 μg/ml in 1998--1999 \[[@pntd.0008137.ref006]\]. In a systematic review of 21 papers reporting fluconazole MIC distributions for clinical cryptococcal isolates, the median MIC~50~ value increased from 4 μg/ml in 2000--2012 to 8 μg/ml in 2014--2018 \[[@pntd.0008137.ref007]\]. In a US study, 37% of isolates collected between 2001 and 2011 had an MIC ≥16 μg/ml, which the authors considered elevated based on a literature review. This study reported an association between elevated fluconazole MIC and prior azole use \[[@pntd.0008137.ref008]\]. Fluconazole is a broad-spectrum antifungal agent with several indications, including cryptococcal antigenaemia, candidaemia, mucosal candidiasis and common fungal skin infections \[[@pntd.0008137.ref009]\]. Fluconazole is commonly prescribed to HIV-seropositive patients; therefore, fluconazole exposure for other indications could result in development of secondary resistance if patients have concurrent active cryptococcal disease \[[@pntd.0008137.ref010]\]. In agriculture, azole fungicides are used to treat crops. Of 229 pesticides registered in South Africa, 22 are azole-based fungicides \[[@pntd.0008137.ref011]\]. Analogous to the emergence of azole-resistant *Aspergillus fumigatus* \[[@pntd.0008137.ref012]\], it is also possible that cryptococcal strains develop resistance to azoles when exposed to fungicides in the environment and some people develop infections with primarily-resistant strains. The aim of this study was to assess whether there was an increase in fluconazole MIC values in South African clinical cryptococcal isolates since the last survey was performed almost ten years ago.

Materials and methods {#sec005}
=====================

Study design {#sec006}
------------

Since 2002, the National Institute for Communicable Diseases (NICD) has conducted laboratory-based surveillance for cryptococcosis. A case has been consistently defined as a person diagnosed with cryptococcal disease at any South African laboratory, based on any one of the following positive tests: India ink test on cerebrospinal fluid (CSF), cryptococcal antigen test on blood or CSF and culture of *Cryptococcus* from any specimen. Using a standardised case report form, study nurses at enhanced surveillance sites collected detailed information from participants who met the laboratory case definition. In an earlier survey, Govender et al. had reported that 3/467 (0.6%) clinical *C*. *neoformans* isolates had fluconazole MICs ≥16 μg/ml \[[@pntd.0008137.ref005]\]. In the 2017 survey, we needed to perform antifungal susceptibility testing on at least 220 *C*. *neoformans* isolates to show a difference in prevalence based on 80% power and an alpha of 0.05, if we hypothesized that the proportion of isolates with a fluconazole MIC ≥8 μg/ml had increased from \<1% to 5%. In the earlier survey, 280 of 571 first episodes of cryptococcosis from 2007--2008 had been randomly selected from four enhanced surveillance hospitals in Gauteng province; 249 viable isolates were then tested for antifungal susceptibility using the same laboratory methods (with no modifications) as detailed in the section below. We prospectively collected *C*. *neoformans* isolates from 1 January through to 31 March 2017 from persons with a first episode of culture-confirmed cryptococcal disease at 37 enhanced and non-enhanced surveillance hospitals across South Africa. Only incident cases were included and these were defined as participants of any age with first isolation of *C*. *neoformans* from any specimen. We thus compared the antifungal susceptibility profiles of *Cryptococcus* isolates collected during 2 surveillance periods: 1 March 2007 through 28 February 2008 (n = 249, Gauteng province) and 1 January 2017 through 31 March 2017 (n = 229, national \[9 provinces\]).

Laboratory methods for 2017 survey {#sec007}
----------------------------------

Isolates were received on Dorset transport medium (Media Mage, Johannesburg, South Africa) at NICD, were confirmed as *C*. *neoformans* species-complex by standard phenotypic methods, then stored at -70°C \[[@pntd.0008137.ref013]\]. Canavanine-glycine-bromothymol blue (CGB) agar has a reported 100% specificity for identification of *C*. *neoformans* and was read after 96h of incubation at 30°C \[[@pntd.0008137.ref014]\]. No *C*. *gattii* isolates were identified. Antifungal susceptibility testing was performed on 229 randomly-selected *C*. *neoformans* isolates from first episodes of cryptococcal disease. All phenotypically-confirmed *C*. *neoformans* isolates submitted to NICD during 2017 were labelled consecutively and we randomly selected isolates (based on our required sample size) using a random integer generator (<https://www.random.org/integers/>). The 229 *C*. *neoformans* isolates were sub-cultured from freezer storage at least twice on Sabouraud agar (Diagnostic Media Products, National Health Laboratory Service \[DMP\], Johannesburg, South Africa) before antifungal susceptibility testing was performed. We determined fluconazole MICs (range: 0.125 μg/ml to 64 μg/ml) using custom-made broth microdilution panels prepared at NICD and inoculated and read according to Clinical and Laboratory Standards Institute M27-A3 and M60 recommendations \[[@pntd.0008137.ref015], [@pntd.0008137.ref016]\]. No technical and biological repeats were performed. However, two independent observers blinded to each other's readings manually read broth microdilution MICs using a reading mirror after 72h of incubation at 35°C. MICs were read at a 50% inhibition endpoint. Each new batch of broth microdilution plates was tested using *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258 as quality control strains. MIC values of *C*. *neoformans* isolates from 2017 were then compared to the MIC values of previously tested isolates from 2007--2008 \[[@pntd.0008137.ref005]\]. For isolates with a fluconazole MIC ≥16 μg/ml, we also determined voriconazole, posaconazole and itraconazole MICs by Etest (bioMérieux, Marcy-l\'Étoile, France) using RPMI agar (Diagnostic Media Products, NHLS, South Africa). MIC endpoints were also read at 50% inhibition for the above antifungal agents after 72h of incubation at 30°C. A small subset of isolates (n = 20) were randomly selected (using the same random selection mentioned above) from 2007--2008, retrieved from -70°C storage and re-tested using the custom-made fluconazole broth microdilution plates to determine whether MIC values matched values recorded previously \[[@pntd.0008137.ref005]\].

Statistical analyses {#sec008}
--------------------

We used chi-square or Fisher's exact tests to compare proportions and the Wilcoxon rank sum test to compare medians between the two surveillance periods using Stata version 14.1 (StataCorp LP, College Station, Texas, USA). We also determined whether prior hospitalisation (as a proxy for exposure to antifungals) was associated with a fluconazole MIC of ≥16 μg/ml. We performed a sensitivity analysis by varying the cut-offs for an elevated fluconazole MIC (≥8 μg/ml and ≥32 μg/ml) \[[@pntd.0008137.ref007]\].

Ethics approval {#sec009}
---------------

Ethics clearance for this study was obtained from the Human Research Ethics Committee (Medical), University of the Witwatersrand. All data analysed was anonymized.

Results {#sec010}
=======

In 2007--2008, there were 571 first episodes of cryptococcosis (Gauteng province), 280 of which were randomly selected; 249 viable isolates from these cases were tested for antifungal susceptibility \[[@pntd.0008137.ref005]\]. From January through to March 2017, there were 260 *C*. *neoformans* isolates from first episodes (national survey) that met the inclusion criteria for antifungal susceptibility testing, 229 of which were randomly selected for antifungal susceptibility testing. In 2007--2008, 55% of participants were female with a median age of 35 years (IQR: 30--40 years). In 2017, 59% were male with a median age of 36 years (IQR: 30--43 years). There were more participants on combination induction antifungal treatment (fluconazole and amphotericin B) included in the 2017 survey compared to 2007--2008 ([Table 1](#pntd.0008137.t001){ref-type="table"}). The 20 *C*. *neoformans* isolates from the 2007--2008 period that were re-tested on the custom-made broth microdilution plates all had fluconazole MIC values within a double dilution of previously-reported MICs ([S1 Table](#pntd.0008137.s002){ref-type="supplementary-material"}). [Table 2](#pntd.0008137.t002){ref-type="table"} and [Fig 1](#pntd.0008137.g001){ref-type="fig"} show the MIC values for the two surveillance periods; in 2007--2008, the geometric mean was 2.08 μg/ml and 4.11 μg/ml in 2017. The MIC~50~ value increased from 1 μg/ml in 2007--2008 to 4 μg/ml in 2017. The MIC~90~ value increased from 2 μg/ml in 2007--2008 to 8 μg/ml in 2017. Voriconazole, itraconazole and posaconazole Etests were performed on 16 of 229 (7%) *C*. *neoformans* isolates with a fluconazole MIC value of ≥16 μg/ml. One isolate had MIC values of \>32 μg/ml for voriconazole, itraconazole and posaconazole. The MIC ranges for the other isolates were 0.0004--1.5 μg/ml, 0.012--2 μg/ml and 0.064--8 μg/ml for voriconazole, itraconazole and posaconazole respectively ([S2 Table](#pntd.0008137.s003){ref-type="supplementary-material"}). We found no evidence of an association between prior hospitalisation and a fluconazole MIC of ≥8 μg/ml (crude odds ratio 1.33, 95% CI: 0.59--3.01; p-value = 0.5) and ≥16 μg/ml (crude odds ratio 0.84, 95% CI: 0.17--4.08; p-value = 0.8). Clinical outcome data for participants in both surveillance periods are shown in [Table 3](#pntd.0008137.t003){ref-type="table"}. We found an 11% increased unadjusted odds of death among those infected with strains with an MIC ≥8 μg/ml (versus \<8 μg/ml), though a 34% reduction to an 86% increase is also compatible with our data (crude odds ratio for death, 1.11; 95% CI: 0.66 to 1.86; p-value = 0.15).

10.1371/journal.pntd.0008137.t001

###### Comparison of patients with cryptococcosis and antifungal susceptibility results during two surveillance periods: 1 March 2007--28 February 2008 and January 2017 --March 2017.

![](pntd.0008137.t001){#pntd.0008137.t001g}

  Characteristic                                                  Number (%)    p value[\*](#t001fn001){ref-type="table-fn"}   
  --------------------------------------------------------------- ------------- ---------------------------------------------- ---------
  **Sex (n = 453)**                                               249           204                                            \<0.001
   Male                                                           98 (39)       124 (61)                                       
   Female                                                         151 (61)      80 (39)                                        
  **Age, years (n = 450)**                                        247           203                                            0.21
   Median (IQR)                                                   35 (30--40)   36 (30--44)                                    
  **HIV status (n = 375)**                                        223           152                                            0.09
   HIV-seropositive                                               223 (100)     150 (99)                                       
   HIV-seronegative                                               0 (0)         2 (1)                                          
  **CD4 count, cells/μl (n = 299)**                               172           127                                            0.17
   0--50                                                          108 (63)      87 (69)                                        
   51--100                                                        35 (20)       22 (17)                                        
   101--200                                                       24 (14)       10 (8)                                         
   \>200                                                          5 (3)         8 (6)                                          
  **Specimen type for positive cryptococcal culture (n = 453)**   249           204                                            0.39
   CSF                                                            218 (88)      172 (84)                                       
   Blood                                                          31 (12)       31 (15)                                        
   Other                                                          0 (0)         1 (1)                                          
  **Antifungal treatment during admission (n = 365)**             235           130                                            \<0.001
   Fluconazole alone                                              121 (51)      5 (4)                                          
   Amphotericin B alone                                           20 (9)        6 (4)                                          
   Fluconazole and amphotericin B                                 75 (32)       119 (92)                                       
   No treatment                                                   19 (8)        0 (0)                                          
  **In-hospital outcome (n = 384)**                               226           158                                            0.68
   Died                                                           84 (37)       62 (39)                                        
   Survived                                                       142 (63)      96 (61)                                        

\*Wilcoxon rank sum test, chi-squared test or Fisher's exact test.

^+^ Number of cases after deduplication performed.

10.1371/journal.pntd.0008137.t002

###### Fluconazole MIC values of cryptococcal isolates collected during 2 surveillance periods: 1 March 2007--28 February 2008 and January 2017 --March 2017.

![](pntd.0008137.t002){#pntd.0008137.t002g}

  MIC value (μg/ml)    Number (%) of isolates   
  -------------------- ------------------------ ---------
  0.125                0 (0)                    0 (0)
  0.25                 1 (1)                    0 (0)
  0.5                  14 (5)                   3 (1)
  1                    53 (21)                  20 (9)
  2                    97 (39)                  50 (22)
  4                    70 (28)                  67 (29)
  8                    14 (6)                   73 (32)
  16                   0 (0)                    14 (6)
  32                   0 (0)                    1 (0.5)
  64                   0 (0)                    1 (0.5)
  **Total**            **249**                  **229**
  **Range**            0.25--8                  0.5--64
  **MIC**~**50**~      1                        4
  **MIC**~**90**~      2                        8
  **Geometric mean**   2.08                     4.11

10.1371/journal.pntd.0008137.t003

###### Association between fluconazole MIC values and clinical outcome of patients with cryptococcosis during two surveillance periods: 1 March 2007--28 February 2008 and January 2017 --March 2017.

![](pntd.0008137.t003){#pntd.0008137.t003g}

  MIC value (μg/ml)   Case-fatality ratio, n/N (%)   
  ------------------- ------------------------------ -------------
  ≤2                  50/165 (30)                    17/66 (26)
  2--4                27/70 (39)                     22/62 (35)
  ≥8                  7/14 (50)                      23/76 (30)
  All                 84/249 (34)                    62/204 (30)

![Fluconazole MIC values of cryptococcal isolates between 2 surveillance periods: 1 March 2007--28 February 2008 (n = 249) and January 2017 --March 2017 (n = 229).](pntd.0008137.g001){#pntd.0008137.g001}

Discussion {#sec011}
==========

Over the last decade, the fluconazole susceptibility of *C*. *neoformans* isolates from a first episode of disease has decreased overall in South Africa. Fluconazole MIC~50~ and MIC~90~ values were two-fold higher in 2017 compared to 2007--2008. The proportion of isolates with a fluconazole MIC ≥16 μg/ml increased from 0% in 2007--2008 to 7% in 2017. This trend is consistent with studies from Uganda \[[@pntd.0008137.ref006]\], USA \[[@pntd.0008137.ref007]\] and Taiwan \[[@pntd.0008137.ref017]\]. Epidemiological cut-off values currently exist for *C*. *neoformans*: non-typed isolates with an MIC value of ≥16 μg/ml are considered to be non-wild-type \[[@pntd.0008137.ref018]\]. These findings have provided impetus for new fluconazole dosing recommendations from the Southern African HIV Clinicians' Society (SAHCS) for management of cryptococcal meningitis \[[@pntd.0008137.ref019], [@pntd.0008137.ref020]\]. Consistent with the antifungal regimens used in the ACTA trial \[[@pntd.0008137.ref021]\], the 2019 SAHCS guideline recommends a fluconazole induction dose of 1200 mg per day (versus 800 mg per day, as previously recommended) in combination with amphotericin B, and a consolidation dose of 800 mg per day (versus previously-recommended 400 mg per day). Based on a MIC~50~ of 4 μg/ml, this will ensure that the area under the curve: MIC ratio (approximated by a daily dose: MIC ratio) is more than 100 for the first 10 weeks of treatment in most cases \[[@pntd.0008137.ref007], [@pntd.0008137.ref022]\]. Flucytosine should ideally be included in combination with either amphotericin B or fluconazole in the induction-phase regimen for meningitis \[[@pntd.0008137.ref021]\]. Although flucytosine is not registered in South Africa, it is currently available through a clinical access programme \[[@pntd.0008137.ref029]\]. The 2019 guideline also recommends that isolates from the first relapse episode be tested for fluconazole susceptibility rather than waiting for repeated relapses to occur before testing \[[@pntd.0008137.ref019], [@pntd.0008137.ref023]\]. Fluconazole inhibits the lanosterol 14α-demethylase enzyme encoded by *ERG11* in the ergosterol biosynthesis pathway and targets the same cell processes as amphotericin B \[[@pntd.0008137.ref006], [@pntd.0008137.ref024]\]. The molecular basis of resistance includes multidrug efflux pump proteins, decreased affinity to target enzymes or overall decreased drug uptake \[[@pntd.0008137.ref007]\]. Heteroresistance which is a phenomenon where strains express a transient adaptation to the drug also occurs \[[@pntd.0008137.ref024], [@pntd.0008137.ref025]\]. These mechanisms of resistance will need to be investigated further in the few *C*. *neoformans* isolates with a high fluconazole MIC from our study. Secondary resistance may occur in patients with active cryptococcal disease who are exposed to azoles or as a consequence of primary infection with resistant cryptococcal strains from the environment due to triazole fungicide exposure \[[@pntd.0008137.ref006]\]. To support the latter hypothesis, a study has shown that cryptococcal strains exposed to the pesticide tebuconazole caused resistance to fluconazole both in vitro and in vivo \[[@pntd.0008137.ref026]\]. We observed low MICs to voriconazole, posaconazole and itraconazole in most *C*. *neoformans* isolates with a fluconazole MIC ≥16 μg/ml. In a Zimbabwean study, isavuconazole, voriconazole, itraconazole and posaconazole had the most potent in vitro activity against *Cryptococcus* isolates from a cohort of patients with cryptococcal meningitis using the CLSI broth microdilution method \[[@pntd.0008137.ref027]\]. These azoles could be used as alternatives to fluconazole though are associated with much higher costs, more adverse effects, more erratic pharmacokinetics and limited availability in most resource-limited settings \[[@pntd.0008137.ref028]\]. Nasri et al. reported that prior azole exposure was associated with a higher fluconazole MIC in immunocompromised persons especially those with HIV infection. They also found that isolates with a fluconazole MIC ≥16 μg/ml were more likely to be cultured from people with central nervous system complications \[[@pntd.0008137.ref007]\]. We could not determine an association between high fluconazole MIC and prior fluconazole exposure due to data sparsity. Although we did not genotype the *C*. *neoformans* isolates collected over the two surveillance periods, most isolates are likely to belong to the VNI genotype since this was the dominant genotype observed in a random sample of South African cryptococcal isolates over a 5-year surveillance period (Naicker SD, unpublished data). We also compared the fluconazole susceptibility profile of *C*. *neoformans* isolates from a national survey in 2017 to those from Gauteng (provincial) surveillance in 2007--2008 which is a limitation. However, nearly half (100/229) of the isolates tested for antifungal susceptibility in 2017 were from Gauteng province, five (31%) of which had a fluconazole MIC ≥16 μg/ml. We did not determine the molecular mechanism of resistance for the 16 *C*. *neoformans* isolates with a MIC of ≥16 μg/ml.

In conclusion, fluconazole MIC~50~ and MIC~90~ values were two-fold higher in clinical South African *C*. *neoformans* isolates collected in 2017 compared to 2007--2008. The resistance mechanisms of these isolates need to be studied further. These study findings provided evidence for higher fluconazole dose recommendations (in combination with amphotericin B for the induction phase and as monotherapy for consolidation and maintenance phases) in the 2019 Southern African guideline for HIV-associated cryptococcosis. Further efforts are needed to make flucytosine available for induction phase treatment.
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